The BC-CfE’s Committee for Drug Evaluation and Therapy has issued and continues to update guidelines regarding SARS-CoV-2 and Persons Living with HIV. Please click the link below to see these statements.
All samples submitted for Drug Resistance Testing will now be tested for susceptibility to Protease and Reverse Transcriptase Inhibitors (nRTIs, NNRTIs, PIs) and Integrase Inhibitors. Separate requests are still required for GP41 drug resistance testing (susceptibility to Fusion Inhibitors) and HIV Coreceptor tropism testing (susceptibility to CCR5 antagonists). Updated requisition forms are available here .
RT @CAHR_ACRV : #CAHR2023 - Content now available and Conference wrap up / Le contenu de l’#ACRV2023 est maintenant disponible, ain… https://t.co/OpCU8xIuzk 2 days ago